These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
309 related articles for article (PubMed ID: 34642880)
1. Prevention of kidney function decline using uric acid-lowering therapy in chronic kidney disease patients: a systematic review and network meta-analysis. Tsukamoto S; Okami N; Yamada T; Azushima K; Yamaji T; Kinguchi S; Uneda K; Kanaoka T; Wakui H; Tamura K Clin Rheumatol; 2022 Mar; 41(3):911-919. PubMed ID: 34642880 [TBL] [Abstract][Full Text] [Related]
2. Effects of uric acid-lowering therapy (ULT) on renal outcomes in CKD patients with asymptomatic hyperuricemia: a systematic review and meta-analysis. Luo Y; Song Q; Li J; Fu S; Yu W; Shao X; Li J; Huang Y; Chen J; Tang Y BMC Nephrol; 2024 Feb; 25(1):63. PubMed ID: 38395818 [TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of urate-lowering agents in asymptomatic hyperuricemia: systematic review and network meta-analysis of randomized controlled trials. Sapankaew T; Thadanipon K; Ruenroengbun N; Chaiyakittisopon K; Ingsathit A; Numthavaj P; Chaiyakunapruk N; McKay G; Attia J; Thakkinstian A BMC Nephrol; 2022 Jun; 23(1):223. PubMed ID: 35739495 [TBL] [Abstract][Full Text] [Related]
4. Changeover Trial of Febuxostat and Topiroxostat for Hyperuricemia with Cardiovascular Disease: Sub-Analysis for Chronic Kidney Disease (TROFEO CKD Trial). Sezai A; Unosawa S; Taoka M; Osaka S; Sekino H; Tanaka M Ann Thorac Cardiovasc Surg; 2020 Aug; 26(4):202-208. PubMed ID: 31748427 [TBL] [Abstract][Full Text] [Related]
5. Comparative effect of allopurinol and febuxostat on long-term renal outcomes in patients with hyperuricemia and chronic kidney disease: a systematic review. Hu AM; Brown JN Clin Rheumatol; 2020 Nov; 39(11):3287-3294. PubMed ID: 32418037 [TBL] [Abstract][Full Text] [Related]
6. Urate-lowering efficacy and renal safety of febuxostat in patients with hyperuricemia and stage 4-5 chronic kidney disease not yet on dialysis: A meta-analysis of observational studies. Jeong HJ; Park WY; Kim SH; Dalbeth N; Son CN Semin Arthritis Rheum; 2022 Oct; 56():152073. PubMed ID: 35914389 [TBL] [Abstract][Full Text] [Related]
7. Febuxostat Therapy for Patients With Stage 3 CKD and Asymptomatic Hyperuricemia: A Randomized Trial. Kimura K; Hosoya T; Uchida S; Inaba M; Makino H; Maruyama S; Ito S; Yamamoto T; Tomino Y; Ohno I; Shibagaki Y; Iimuro S; Imai N; Kuwabara M; Hayakawa H; Ohtsu H; Ohashi Y; Am J Kidney Dis; 2018 Dec; 72(6):798-810. PubMed ID: 30177485 [TBL] [Abstract][Full Text] [Related]
8. Comparison of uric acid reduction and renal outcomes of febuxostat vs allopurinol in patients with chronic kidney disease. Peng YL; Tain YL; Lee CT; Yang YH; Huang YB; Wen YH; Hsu CN Sci Rep; 2020 Jul; 10(1):10734. PubMed ID: 32612180 [TBL] [Abstract][Full Text] [Related]
9. Effectiveness of Drug Treatments for Lowering Uric Acid on Renal Function in Patients With Chronic Kidney Disease and Hyperuricemia: A Network Meta-Analysis of Randomized Controlled Trials. Liu X; Qiu Y; Li D; Tan J; Liang X; Qin W Front Pharmacol; 2021; 12():690557. PubMed ID: 34413775 [No Abstract] [Full Text] [Related]
10. Urate-Lowering Therapy in Moderate to Severe Chronic Kidney Disease. Levy G; Shi JM; Cheetham TC; Rashid N Perm J; 2018; 22():17-142. PubMed ID: 30201087 [TBL] [Abstract][Full Text] [Related]
11. Comparison of renoprotective effects of febuxostat and allopurinol in hyperuricemic patients with chronic kidney disease. Lee JW; Lee KH Int Urol Nephrol; 2019 Mar; 51(3):467-473. PubMed ID: 30604229 [TBL] [Abstract][Full Text] [Related]
12. Cardiovascular effects of urate-lowering therapies in patients with chronic gout: a systematic review and meta-analysis. Zhang T; Pope JE Rheumatology (Oxford); 2017 Jul; 56(7):1144-1153. PubMed ID: 28379501 [TBL] [Abstract][Full Text] [Related]
13. Comparison of febuxostat and allopurinol for hyperuricemia in cardiac surgery patients with chronic kidney disease (NU-FLASH trial for CKD). Sezai A; Soma M; Nakata K; Osaka S; Ishii Y; Yaoita H; Hata H; Shiono M J Cardiol; 2015 Oct; 66(4):298-303. PubMed ID: 25649025 [TBL] [Abstract][Full Text] [Related]
14. Urate-lowering drugs for chronic kidney disease with asymptomatic hyperuricemia and hypertension: a randomized trial. Kohagura K; Satoh A; Kochi M; Nakamura T; Zamami R; Tana T; Kinjyo K; Funakoshi R; Yamazato M; Ishida A; Sakima A; Iseki K; Arima H; Ohya Y J Hypertens; 2023 Sep; 41(9):1420-1428. PubMed ID: 37334544 [TBL] [Abstract][Full Text] [Related]
15. Efficacy of febuxostat in hyperuricemic patients with mild-to-moderate chronic kidney disease: a meta-analysis of randomized clinical trials: A PRISMA-compliant article. Zeng XX; Tang Y; Hu K; Zhou X; Wang J; Zhu L; Liu J; Xu J Medicine (Baltimore); 2018 Mar; 97(13):e0161. PubMed ID: 29595642 [TBL] [Abstract][Full Text] [Related]
16. Efficacy of Febuxostat for Slowing the GFR Decline in Patients With CKD and Asymptomatic Hyperuricemia: A 6-Month, Double-Blind, Randomized, Placebo-Controlled Trial. Sircar D; Chatterjee S; Waikhom R; Golay V; Raychaudhury A; Chatterjee S; Pandey R Am J Kidney Dis; 2015 Dec; 66(6):945-50. PubMed ID: 26233732 [TBL] [Abstract][Full Text] [Related]
17. Comparison of long-term efficacy and renal safety of febuxostat and allopurinol in patients with chronic kidney diseases . Yang AY Int J Clin Pharmacol Ther; 2020 Jan; 58(1):21-28. PubMed ID: 31657714 [TBL] [Abstract][Full Text] [Related]
18. Febuxostat as a renoprotective agent for treatment of hyperuricaemia: a meta-analysis of randomised controlled trials. Chewcharat A; Chen Y; Thongprayoon C; Harrison AM; Mao MA; Cheungpasitporn W Intern Med J; 2021 May; 51(5):752-762. PubMed ID: 32149437 [TBL] [Abstract][Full Text] [Related]
19. Effect of Febuxostat versus Allopurinol on the Glomerular Filtration Rate and Hyperuricemia in Patients with Chronic Kidney Disease. Nagaraju SP; Shenoy SV; Rao I; Prabhu RA; Rangaswamy D; Bhojaraja MV; Guddattu V Saudi J Kidney Dis Transpl; 2023 Jul; 34(4):279-287. PubMed ID: 38345582 [TBL] [Abstract][Full Text] [Related]
20. Efficacy of Urate-Lowering Therapy in Patients With Chronic Kidney Disease: A Network Meta-Analysis of Randomized Controlled Trials. Yu X; Gu M; Zhu Y; Zhang L; Kong W; Zou Y Clin Ther; 2022 May; 44(5):723-735.e6. PubMed ID: 35610080 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]